Guinea worm on track to be 2nd eradicated human disease; only 10 cases in 2025

Animal reservoirs and eradication challenges

• Commenters note that while human cases are near zero, several hundred animal cases across six countries remain, which still requires full surveillance and intervention infrastructure.
• There is debate on how many animal infections go undetected, especially in wild hosts; numbers reported are understood to be “known” cases, not necessarily totals.
• Discussion notes that animal reservoirs (dogs, cats, baboons) were only confirmed in the 2010s, delaying full eradication timelines.
• Some argue eradication is still plausible because the parasite seems to reproduce best in humans; cutting human transmission may starve animal reservoirs over time.
• Others are skeptical about reliably eliminating infection from wild animals at all, questioning whether true eradication is possible.

Magnitude of progress and human perception of risk

• Participants highlight the drop from millions of human cases to a few dozen as astonishing progress.
• Several comments explore how small animal numbers (e.g., a few hundred cases) can “feel” large because they are more cognitively graspable than millions, even though they are orders of magnitude smaller.

Incentive-based surveillance (cash bounties)

• The program’s use of cash rewards for reporting suspected cases is seen as a clever surveillance mechanism.
• Some worry about a “cobra effect” (people deliberately creating cases to collect bounties), but others point out the rewards are small and social consequences for intentional infection would be severe; empirically, it seems to have worked.

Ivermectin and parasitic disease tangent

• A subthread clarifies that ivermectin, while a highly effective dewormer (and WHO essential medicine), does not work on Guinea worm.
• People discuss its legitimate uses (onchocerciasis, lymphatic filariasis, scabies, bedbugs) and how mass deworming could have confounded some COVID studies.
• There is debate over media framing of ivermectin as merely a “horse dewormer” versus acknowledging its established human uses and Nobel-recognized impact.

Broader reflections: institutions, markets, and optimism

• Many comments credit the Carter Center and similar organizations for sustained, difficult field work in conflict-affected regions.
• A wider debate contrasts philanthropy, taxation, and “free market” narratives in achieving public health milestones.
• The success against Guinea worm is used both to argue for human capability to solve big problems and to critique ongoing failures, especially around basic needs like clean water.